Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7156807 | 1.00 | OPRD1 (0.47) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL20522864 | 0.83 | OPRD1 (0.57) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL20522865 | 0.83 | OPRD1 (0.57) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL17433720 | 0.83 | OPRD1 (0.57) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL4860126 | 0.83 | HDAC8 (0.53) | OPRD1OPRM1OPRK1 | |
| SCHEMBL4859793 | 0.83 | OPRD1 (0.48) | OPRD1OPRM1OPRK1ACEPOLB | |
| SCHEMBL14279605 | 0.83 | HDAC8 (0.53) | OPRD1OPRM1OPRK1 | |
| SCHEMBL28764419 | 0.83 | OPRD1 (0.48) | OPRD1OPRM1OPRK1ACEPOLB | |
| SCHEMBL23361203 | 0.82 | POLB (0.50) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL9849102 | 0.82 | POLB (0.50) | OPRD1OPRM1OPRK1AGTR2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | OPRD1 1398/4885OPRM1 571/4885OPRK1 1001/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | OPRD1 1398/4885OPRM1 571/4885OPRK1 1001/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | OPRD1 1398/4885OPRM1 571/4885OPRK1 1001/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | OPRD1 1370/4885OPRM1 572/4885OPRK1 1026/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | OPRD1 1398/4885OPRM1 571/4885OPRK1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.